LIQUIDIA CORP (LQDA) Fundamental Analysis & Valuation

NASDAQ:LQDA • US53635D2027

Current stock price

36.63 USD
-0.23 (-0.62%)
At close:
36.0372 USD
-0.59 (-1.62%)
After Hours:

This LQDA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. LQDA Profitability Analysis

1.1 Basic Checks

  • In the past year LQDA has reported negative net income.
  • LQDA had a negative operating cash flow in the past year.
  • LQDA had negative earnings in each of the past 5 years.
  • In the past 5 years LQDA always reported negative operating cash flow.
LQDA Yearly Net Income VS EBIT VS OCF VS FCFLQDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • LQDA has a Return On Assets (-21.02%) which is comparable to the rest of the industry.
  • With a Return On Equity value of -154.03%, LQDA is not doing good in the industry: 70.31% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -21.02%
ROE -154.03%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LQDA Yearly ROA, ROE, ROICLQDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200

1.3 Margins

  • LQDA has a Gross Margin of 91.64%. This is amongst the best in the industry. LQDA outperforms 94.27% of its industry peers.
  • In the last couple of years the Gross Margin of LQDA has grown nicely.
  • LQDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.75%
GM growth 5Y6.28%
LQDA Yearly Profit, Operating, Gross MarginsLQDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. LQDA Health Analysis

2.1 Basic Checks

  • LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for LQDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LQDA Yearly Shares OutstandingLQDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
LQDA Yearly Total Debt VS Total AssetsLQDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 4.55 indicates that LQDA is not in any danger for bankruptcy at the moment.
  • LQDA has a Altman-Z score of 4.55. This is in the better half of the industry: LQDA outperforms 75.52% of its industry peers.
  • LQDA has a Debt/Equity ratio of 2.97. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 2.97, LQDA is not doing good in the industry: 80.73% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.97
Debt/FCF N/A
Altman-Z 4.55
ROIC/WACCN/A
WACC9.33%
LQDA Yearly LT Debt VS Equity VS FCFLQDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M

2.3 Liquidity

  • LQDA has a Current Ratio of 2.01. This indicates that LQDA is financially healthy and has no problem in meeting its short term obligations.
  • LQDA's Current ratio of 2.01 is on the low side compared to the rest of the industry. LQDA is outperformed by 60.42% of its industry peers.
  • A Quick Ratio of 1.84 indicates that LQDA should not have too much problems paying its short term obligations.
  • LQDA has a Quick ratio of 1.84. This is comparable to the rest of the industry: LQDA outperforms 43.75% of its industry peers.
Industry RankSector Rank
Current Ratio 2.01
Quick Ratio 1.84
LQDA Yearly Current Assets VS Current LiabilitesLQDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. LQDA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 51.50% over the past year.
  • LQDA shows a strong growth in Revenue. In the last year, the Revenue has grown by 1031.18%.
  • Measured over the past years, LQDA shows a very strong growth in Revenue. The Revenue has been growing by 192.46% on average per year.
EPS 1Y (TTM)51.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%136.96%
Revenue 1Y (TTM)1031.18%
Revenue growth 3Y114.96%
Revenue growth 5Y192.46%
Sales Q2Q%3054.65%

3.2 Future

  • LQDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.29% yearly.
  • Based on estimates for the next years, LQDA will show a very strong growth in Revenue. The Revenue will grow by 49.95% on average per year.
EPS Next Y332.55%
EPS Next 2Y134.34%
EPS Next 3Y92.34%
EPS Next 5Y59.29%
Revenue Next Year219.14%
Revenue Next 2Y101.67%
Revenue Next 3Y72.11%
Revenue Next 5Y49.95%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LQDA Yearly Revenue VS EstimatesLQDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
LQDA Yearly EPS VS EstimatesLQDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. LQDA Valuation Analysis

4.1 Price/Earnings Ratio

  • LQDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • LQDA is valuated rather expensively with a Price/Forward Earnings ratio of 19.45.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of LQDA indicates a somewhat cheap valuation: LQDA is cheaper than 79.17% of the companies listed in the same industry.
  • LQDA is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.80, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 19.45
LQDA Price Earnings VS Forward Price EarningsLQDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LQDA Per share dataLQDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • LQDA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • LQDA's earnings are expected to grow with 92.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y134.34%
EPS Next 3Y92.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LQDA Dividend Analysis

5.1 Amount

  • LQDA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LQDA Fundamentals: All Metrics, Ratios and Statistics

LIQUIDIA CORP

NASDAQ:LQDA (3/18/2026, 8:20:40 PM)

After market: 36.0372 -0.59 (-1.62%)

36.63

-0.23 (-0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-05
Earnings (Next)05-06
Inst Owners69.38%
Inst Owner Change-6.23%
Ins Owners4.3%
Ins Owner Change1.86%
Market Cap3.19B
Revenue(TTM)158.32M
Net Income(TTM)-68.92M
Analysts82.67
Price Target46.58 (27.16%)
Short Float %16.14%
Short Ratio5.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)41.3%
Min EPS beat(2)-7.63%
Max EPS beat(2)90.23%
EPS beat(4)1
Avg EPS beat(4)15.04%
Min EPS beat(4)-11.43%
Max EPS beat(4)90.23%
EPS beat(8)2
Avg EPS beat(8)-1.47%
EPS beat(12)2
Avg EPS beat(12)-18.47%
EPS beat(16)5
Avg EPS beat(16)-10.57%
Revenue beat(2)2
Avg Revenue beat(2)95.44%
Min Revenue beat(2)7.87%
Max Revenue beat(2)183%
Revenue beat(4)3
Avg Revenue beat(4)74.69%
Min Revenue beat(4)-6.33%
Max Revenue beat(4)183%
Revenue beat(8)4
Avg Revenue beat(8)21.18%
Revenue beat(12)6
Avg Revenue beat(12)13.66%
Revenue beat(16)9
Avg Revenue beat(16)13.15%
PT rev (1m)0%
PT rev (3m)3.79%
EPS NQ rev (1m)-16.65%
EPS NQ rev (3m)0.19%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.52%
Revenue NQ rev (1m)11.74%
Revenue NQ rev (3m)19.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)20.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 19.45
P/S 20.13
P/FCF N/A
P/OCF N/A
P/B 71.22
P/tB 84.1
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)1.88
Fwd EY5.14%
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS1.82
BVpS0.51
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.02%
ROE -154.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.64%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.75%
GM growth 5Y6.28%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 2.97
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 414.66%
Cap/Sales 4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.01
Quick Ratio 1.84
Altman-Z 4.55
F-Score5
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)439.2%
Cap/Depr(5y)267.14%
Cap/Sales(3y)42.98%
Cap/Sales(5y)26.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%136.96%
EPS Next Y332.55%
EPS Next 2Y134.34%
EPS Next 3Y92.34%
EPS Next 5Y59.29%
Revenue 1Y (TTM)1031.18%
Revenue growth 3Y114.96%
Revenue growth 5Y192.46%
Sales Q2Q%3054.65%
Revenue Next Year219.14%
Revenue Next 2Y101.67%
Revenue Next 3Y72.11%
Revenue Next 5Y49.95%
EBIT growth 1Y57.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year569.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.8%
OCF growth 3YN/A
OCF growth 5YN/A

LIQUIDIA CORP / LQDA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LIQUIDIA CORP (LQDA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to LQDA.


What is the valuation status of LIQUIDIA CORP (LQDA) stock?

ChartMill assigns a valuation rating of 3 / 10 to LIQUIDIA CORP (LQDA). This can be considered as Overvalued.


What is the profitability of LQDA stock?

LIQUIDIA CORP (LQDA) has a profitability rating of 2 / 10.


What is the financial health of LIQUIDIA CORP (LQDA) stock?

The financial health rating of LIQUIDIA CORP (LQDA) is 3 / 10.